Document:

EX-10.5

 Exhibit 10.5 

Name: ___________________ 

Position: _________________ 

Effective Date: ____________ 

INDEMNIFICATION AGREEMENT 

This INDEMNIFICATION AGREEMENT (“Agreement”), effective as of the effective date set forth above, is by and between
Comera Life Sciences Holdings, Inc., a Delaware corporation (“Company”), and the director and/or officer of the Company identified above (“Executive”). Certain defined terms used in this Agreement are set forth in
Paragraph 15. 
 WITNESSETH: 

WHEREAS, the Statute, which sets forth certain provisions relating to the mandatory and permissive indemnification of directors and officers
(amongst others) of a Delaware corporation by such corporation, is specifically not exclusive of other rights to which those indemnified thereunder may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or
otherwise and, thus, does not by itself limit the extent to which the Company may indemnify or advance expenses to persons serving as its directors and officers (amongst others); 

WHEREAS, in order to induce and encourage highly experienced and capable individuals, such as the Executive, to serve as a director and/or
officer of the Company and to otherwise promote the desirable end that such directors and officers will feel unrestrained by the threat of incurring personal liability and, therefore, take the business and entrepreneurial risks necessary to ensure
the continued success and growth of the Company, secure in the knowledge that they will receive the maximum indemnification protection against such risks and liabilities as may be afforded by law, the Board has determined, after due consideration
and investigation of the terms and provisions of this Agreement, in light of the circumstances and considerations set forth in these recitals and in the exercise of its good faith business judgment, that this Agreement is not only reasonable, fair
and prudent, but also necessary to promote and ensure the best interests of the Company and its stockholders; 
 WHEREAS, in entering into
this Agreement, both the Company and the Executive represent and agree, to the best of their knowledge, that at present there is no pending litigation or proceeding involving the Executive or any other director and/or officer of the Company where
indemnification or advancement of Expenses under this Agreement (or other similar agreement or provision) would be required or permitted, nor does the Company or the Executive, to the best of their knowledge, know of any threatened litigation or
proceeding or set of existing facts which may result in a claim for indemnification or advancement of Expenses under this Agreement (or under any other similar agreement or provision) by the Executive or any other director and/or officer; and 

WHEREAS, the Company desires to have the Executive serve as a director and/or officer of the Company, free from undue concern for
unpredictable, inappropriate and/or unreasonable legal risks and personal liabilities by reason of performing his or her duties to the Company and its stockholders or his or her status as such as a director and/or officer; and the Executive desires
to serve as a director and/or officer of the Company; provided, and on the express condition, that he or she is furnished with the protections set forth hereinafter. 

 NOW, THEREFORE, in consideration of Executive’s continued service to the Company and in
consideration of the premises, mutual covenants and agreements of the parties contained herein and the mutual benefits to be derived from this Agreement, and the delivery of other good and valuable consideration by the Executive, the receipt and
sufficiency of which is hereby acknowledged by the Company, the parties hereto, intending to be legally bound, hereby covenant and agree as follows: 

1. Indemnification. 

A. The Company hereby covenants and agrees, subject to the conditions and limitations set forth hereinafter in this Paragraph 1 and elsewhere
in this Agreement, to indemnify and hold the Executive harmless if he or she is or was a party, or is threatened to be made a party, to any Action by reason of his or her status as, or the fact that he or she is or was or has agreed to become, a
director and/or officer of the Company, and/or is or was serving or has agreed to serve as a director and/or officer of an Affiliate, and/or as to acts performed (or not performed) in the course of the Executive’s duties to the Company and/or
to an Affiliate, against Liabilities and reasonable Expenses incurred by or on behalf of the Executive in connection with any Action, including, without limitation, in connection with the investigation, defense, settlement or appeal of any Action;
provided, that it is not determined by the Authority, or by a court, pursuant to Paragraph 3 that the Executive has engaged in misconduct which constitutes a Breach of Duty. 

B. To the extent the Executive has been successful on the merits or otherwise in connection with any Action, including, without limitation,
the settlement, dismissal, abandonment or withdrawal of any such Action where the Executive does not pay, incur or assume any material Liabilities, or in connection with any claim, issue or matter therein, he or she shall be indemnified by the
Company against reasonable Expenses incurred by or on behalf of him or her in connection therewith. The Company shall pay such Expenses to the Executive (net of all Expenses, if any, previously advanced to the Executive pursuant to Paragraph 2), or
to such other person or entity as the Executive may designate in writing to the Company, within ten (10) days after the receipt of the Executive’s written request therefor, without regard to the provisions of Paragraph 3. 

C. Notwithstanding any other provision contained in this Agreement to the contrary, the Company shall not: 

(i) indemnify or advance Expenses to the Executive with respect to any Action initiated or brought voluntarily by the Executive (including any
proceedings against the Company or its directors, officers, employees or other indemnitees and not by way of defense), except with respect to Actions: 

(a) brought to establish or enforce a right to indemnification and/or an advancement of Expenses under this Agreement or under
the Statute as it may then be in effect or any other applicable statute or law or otherwise as required (unless a court of competent jurisdiction determines that each of the material assertions made by the Executive in such proceeding was not made
in good faith or was frivolous); or 

  
 - 2 - 

 (b) as to which the Board has consented to the initiation of such
proceedings; 
 (ii) indemnify the Executive against judgments, fines or penalties incurred in a Derivative Action if the Executive is
finally adjudged liable to the Company by a court (unless the court before which such Derivative Action was brought determines that the Executive is fairly and reasonably entitled to indemnity for any or all of such judgments, fines or penalties);
or 
 (iii) indemnify the Executive under this Agreement for any amounts paid in settlement or any Action effected without the
Company’s written consent. 
 D. The Company shall not settle any Action in any manner which would impose any Liabilities or other type
of limitation on the Executive without the Executive’s written consent. Neither the Company nor the Executive shall unreasonably withhold its, his or her consent to any proposed settlement. 

E. The Executive’s conduct with respect to an employee benefit plan sponsored by or otherwise associated with the Company and/or an
Affiliate for a purpose he or she reasonably believed to be in the interests of the participants in, and/or beneficiaries of, such plan is conduct which does not constitute a breach or failure to perform his or her duties to the Company or an
Affiliate, as the case may be. 
 2. Advance Payment of Expenses. 

A. The Company shall pay to the Executive, or such other person or entity as the Executive may designate in writing to the Company, in advance
of the final disposition or conclusion of any Action (or claim, issue or matter associated with such Action) the Executive’s reasonable Expenses incurred by or on behalf of the Executive in connection with such Action (or claim, issue or matter
associated with any such Action), within ten (10) days after the receipt of Executive’s written request therefor; provided, the following conditions are satisfied: 

(i) the Executive furnishes to the Company an executed, written statement affirming his or her good faith belief that he or she has not
engaged in misconduct constituting a Breach of Duty; and 
 (ii) the Executive furnishes to the Company an executed, written agreement to
repay any advances made under this Paragraph 2 if it is ultimately determined that he or she is not entitled to be indemnified by the Company for such Expenses pursuant to this Agreement. 

B. In the event the Company makes an advancement of Expenses to the Executive pursuant to this Paragraph 2, the Company shall be subrogated to
every right of recovery the Executive may have against any insurance carrier from whom the Company has purchased insurance for such purpose. 

  
 - 3 - 

 3. Determination of Right to Indemnification. 

A. Except as otherwise set forth in this Paragraph 3, any indemnification to be provided to the Executive by the Company under Paragraph 1A of
this Agreement upon the final disposition or conclusion of any Action, or a claim, issue or matter associated with any such Action, unless otherwise ordered by a court, shall be paid by the Company to the Executive (net of all Expenses, if any,
previously advanced to the Executive pursuant to Paragraph 2), or to such other person or entity as the Executive may designate in writing to the Company, within thirty (30) days after the receipt of Executive’s written request therefor.
Such request shall include an accounting of all amounts for which indemnification is being sought. No further corporate authorization for such payment shall be required other than this Paragraph 3A. 

B. Notwithstanding the foregoing, the payment of such requested indemnifiable amounts pursuant to Paragraph 1A may be denied by the Company if
the Board, by a majority vote thereof, determines that the Executive engaged in misconduct which constitutes a Breach of Duty; provided, however, to that to the extent that a majority of the Board are party in interest to such Action, then the
payment of such requested indemnifiable amounts pursuant to Paragraph 1A may be denied by the Company by a majority vote of disinterested directors of the Board finding that that the Executive engaged in misconduct which constitutes a Breach of
Duty. In either event of nonpayment, the Board shall immediately authorize and direct, by resolution, that an independent determination be made as to whether the Executive engaged in misconduct which constitutes a Breach of Duty and, therefore,
whether indemnification of the Executive is proper pursuant to this Agreement. 
 C. Such independent determination shall be made
(i) if no Change in Control has occurred, (A) by a majority vote of the disinterested directors, even if less than a quorum of the Board, (B) by a committee of disinterested directors designated by a majority vote of the disinterested
directors, even though less than a quorum or (C) if there are no such disinterested directors, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered to the Executive; and (ii) if a Change in
Control shall have occurred, (A) if the Executive so requests in writing, by a majority vote of the disinterested directors, even if less than a quorum of the Board or (B) otherwise, by Independent Counsel in a written opinion addressed to
the Board, a copy of which shall be delivered to Indemnitee. 
 The Company shall indemnify and hold harmless Executive against and, if
requested by Executive, shall reimburse Executive for, or advance to Executive, within 20 days of such request, any and all Expenses incurred by Executive in cooperating with the person or persons making such independent determination. 

D. In the event a panel of arbitrators is to be employed hereunder pursuant to Paragraph 3C, one of such arbitrators shall be selected by the
Board, by a majority vote of a quorum thereof consisting of directors who were not parties in interest to such Action (or, if such quorum is not obtainable, by an independent legal counsel chosen by a majority vote of the entire Board), the second
by the Executive and the third by the previous two arbitrators. 

  
 - 4 - 

 E. In the event a panel of arbitrators or independent legal counsel is to be employed
hereunder pursuant to Paragraph 3C: (i) the Authority shall make its independent determination hereunder within thirty (30) days of being selected and shall simultaneously submit a written opinion of its conclusions to both the Company and
the Executive; and, (ii) in the event the Authority determines that the Executive is entitled to be indemnified for any amounts pursuant to this Agreement, the Company shall pay such amounts to the Executive (net of all Expenses, if any,
previously advanced to the Executive pursuant to Paragraph 2), including interest thereon as provided in Paragraph 5C, or to such other person or entity as the Executive may designate in writing to the Company, within ten (10) days of receipt
of such opinion. 
 F. In the event a court of competent jurisdiction is to be employed hereunder pursuant to Paragraph 3C and such court
determines that the Executive is entitled to be indemnified for any amounts pursuant to this Agreement, the Company shall pay such amounts to the Executive (net of all Expenses, if any, previously advanced to the Executive pursuant to Paragraph 2),
including interest thereon as provided in Paragraph 5C, or to such other person or entity as the Executive may designate in writing to the Company, within ten (10) days of receipt of such final judicial determination. 

G. Each party shall pay its own Expenses associated with the indemnification process set forth in this Paragraph 3; provided that,
(i) the Company, on the hand, and the Executive, on the other hand, shall each be responsible for 50% of the fees and expenses of the Authority (to the extent a panel of arbitrators or independent legal counsel is to be employed hereunder
pursuant to Paragraph 3C) and (ii) in the event a court of competent jurisdiction is to be employed hereunder pursuant to Paragraph 3C, all Expenses incurred by the Executive in connection with any subsequent appeal of any such judicial
determination shall be paid by the Executive regardless of the disposition of such appeal. 
 4. Termination of an Action
Nonconclusive. The adverse termination of any Action against the Executive by judgment, order, settlement, conviction, or upon a plea of no contest or its equivalent, shall not, of itself, create a presumption that the Executive has engaged in
misconduct which constitutes a Breach of Duty. 
 5. Partial Indemnification; Reasonableness; Interest. 

A. In the event it is determined by the Authority, or by a court, that the Executive is entitled to indemnification as to some claims, issues
or matters, but not as to other claims, issues or matters, involved in any Action, the Authority, or the court, shall authorize the reasonable proration and payment by the Company of such Liabilities and/or reasonable Expenses, with respect to which
indemnification is sought by the Executive, among such claims, issues or matters as the Authority, or the court, shall deem appropriate in light of all of the circumstances of such Action. 

B. In the event it is determined by the Authority, or by a court, that certain Expenses incurred by the Executive are for whatever reason
unreasonable in amount, the Authority, or the court, shall nonetheless authorize indemnification or advancement to be paid by the Company to the Executive for such Expenses as the Authority, or the court, shall deem reasonable in light of all of the
circumstances of such Action. 
 C. Interest shall be paid by the Company to the Executive, to the extent deemed appropriate by the
Authority, or a court, at a reasonable interest rate, for amounts for which the Company indemnifies or advances to the Executive. 

  
 - 5 - 

 6. Insurance; Subrogation. 

A. The Company may purchase and maintain insurance on behalf of the Executive against any Liability and/or Expense asserted against him or her
and/or incurred by or on behalf of him or her in such capacity as a director and/or officer or other employee or agent of the Company and/or of an Affiliate, or arising out of his or her status as such, whether or not the Company would have the
power to indemnify him or her against such Liability or advancement of Expenses under the provisions of this Agreement or under the Statute as it may then be in effect. Except as expressly provided herein, the purchase and maintenance of such
insurance shall not in any way limit or affect the rights and obligations of the Company and/or the Executive under this Agreement and the execution and delivery of this Agreement by the Company and the Executive shall not in any way be construed to
limit or affect the rights and obligations of the Company and/or of the other party or parties thereto under any such policy or agreement of insurance. 

B. In the event the Executive shall receive payment from any insurance carrier and/or from the plaintiff in any Action against the Executive
in respect of indemnified or advanced amounts after payments on account of all or part of such indemnified or advanced amounts have been made by the Company pursuant to this Agreement, the Executive shall promptly reimburse the Company for the
amount, if any, by which the sum of such payment by such insurance carrier and/or such plaintiff and payments by the Company to the Executive exceeds such indemnified or advanced amounts; provided, however, that such portions, if any, of such
insurance proceeds that are required to be reimbursed to the insurance carrier under the terms of its insurance policy, such as co-insurance, retention or deductible amounts, shall not be deemed to be payments
to the Executive hereunder. 
 C. In addition, upon payment of indemnified or advanced amounts under this Agreement, the Company shall be
subrogated to the Executive’s rights against any insurance carrier in respect of such indemnified or advanced amounts, and the Executive shall execute and deliver any and all instruments and/or documents and perform any and all other acts or
deeds which the Company deems necessary or advisable to secure such rights. The Executive shall do nothing to prejudice such rights of recovery or subrogation. 

7. Witness Expenses. The Company shall pay in advance or reimburse any and all reasonable Expenses incurred by the Executive in
connection with his or her appearance as a witness in any Action at a time when he or she has not been formally named a defendant or respondent to such an Action, within ten (10) days after the receipt of the Executive’s written request
therefor. 
 8. Nonexclusivity of Agreement. The rights to indemnification and the advancement of Expenses provided to the Executive
by this Agreement shall not be deemed exclusive of any other rights to which the Executive may be entitled under any charter provision, bylaw, agreement, resolution, vote of stockholders or disinterested directors of the Company or otherwise,
including, without limitation, under the Statute as it may then be in effect, both as to 

  
 - 6 - 

 
acts in his or her official capacity as such director, officer or other employee or agent of the Company and/or of an Affiliate or as to acts in any other capacity while holding such office or
position, whether or not the Company would otherwise have the power to indemnify, contribute or advance Expenses to the Executive. Further, nothing contained in this Agreement shall in any way limit or otherwise affect any rights to indemnification
or advancement of expenses that the Executive may have pursuant to the terms of any agreement between the Executive and the Company related to periods prior to the effective date hereof. 

9. Notice to the Company; Defense of Actions. 

A. The Executive agrees to promptly notify the Company in writing upon being served with or having actual knowledge of any citation, summons,
complaint, indictment or any other similar document relating to any Action which may result in a claim of indemnification or advancement of Expenses hereunder, but the omission so to notify the Company will not relieve the Company from any liability
which it may have to the Executive otherwise than under this Agreement unless the Company shall have been irreparably prejudiced by such omission. 

B. With respect to any such Action as to which the Executive notifies the Company of the commencement thereof, except as otherwise provided
below in Paragraph 9C, the Company (or any other indemnifying party, including any insurance carrier, similarly notified by the Executive and/or the Company) shall be entitled to assume the defense thereof, with counsel selected by the Company (or
such other indemnifying party) and reasonably satisfactory to the Executive, or if the Company (or any other indemnifying party) does not assume the defense thereof, the Company shall be entitled to participate therein at its own expense. 

C. After notice from the Company (or such other indemnifying party) to the Executive of its election to assume the defense of an Action, the
Company shall not be liable to the Executive under this Agreement for any Expenses subsequently incurred by the Executive in connection with the defense thereof, other than reasonable costs of investigation or as otherwise provided below. The
Executive shall have the right to employ his or her counsel in such Action but the Expenses of such counsel incurred after notice from the Company (or such other indemnifying party) of its assumption of the defense thereof shall be at the expense of
the Executive unless: (i) the employment of counsel by the Executive has been authorized by the Company; (ii) the Executive shall have reasonably concluded that there may be a conflict of interest between the Company (or such other
indemnifying party) and the Executive in the conduct of the defense of such Action; (iii) after a Change in Control, Executive’s employment of its own counsel has been approved by the Independent Counsel or (iv) the Company (or such
other indemnifying party) shall not in fact have employed counsel to assume the defense of such Action, in each of which cases the Expenses of counsel shall be at the expense of the Company. The Company shall not be entitled to assume the
defense of any Derivative Action or any Action as to which the Executive shall have made the conclusion provided for in clause (ii) above. 

10. Continuation of Rights and Obligations. Subject to Paragraph 14, the terms and provisions of this Agreement shall continue as to
the Executive subsequent to the Termination Date, and such terms and provisions shall inure to the benefit of the heirs, executors, estate and administrators of the Executive and the successors and assigns of the Company, including, without
limitation, any successor to the Company by way of merger, consolidation and/or sale or 

  
 - 7 - 

 
disposition of all or substantially all of the assets or capital stock of the Company. Except as provided herein, all rights and obligations of the Company and the Executive hereunder shall
continue in full force and effect despite the subsequent amendment or modification of the Company’s Certificate of Incorporation or bylaws, as such are in effect on the date hereof, and such rights and obligations shall not be affected by any
such amendment or modification, any resolution of directors or stockholders of the Company, or by any other corporate action which conflicts with or purports to amend, modify, limit or eliminate any of the rights or obligations of the Company and/or
of the Executive hereunder. 
 11. Amendment and Modification. This Agreement may only be amended, modified or supplemented by the
written agreement of the Company and the Executive, and any such mutually agreed upon amendment, modification or supplement shall not require stockholder or Board approval and/or ratification if such amendment, modification or supplement: 

(i) is made in order to conform to or reflect any amendment or revision of the DGCL, including, without limitation, the Statute, which
(a) expands or permits the expansion of the Executive’s rights to indemnification or advancement of Expenses thereunder; (b) limits or eliminates, or permits the limitation or elimination, of the liability of the Executive; or
(c) or is otherwise beneficial to the Executive; or 
 (ii) in the sole judgment and discretion of the Board, does not materially
adversely affect the rights and protections of the stockholders of the Company. 
 12. Governing Law. All matters with respect to
this Agreement, including, without limitation, matters of validity, construction, effect and performance shall be governed by the internal laws of the State of Delaware applicable to contracts made and to be performed therein between the residents
thereof (regardless of the laws that might otherwise be applicable under principles of conflicts of law). 
 13. Counterparts. This
Agreement may be executed in two or more fully or partially executed counterparts each of which shall be deemed an original binding the signer thereof against the other signing parties, but all counterparts together shall constitute one and the same
instrument. Executed signature pages may be delivered by any electronic means and may be removed from counterpart agreements and attached to one or more fully executed copies of this Agreement. 

14. Severability. If any provision of this Agreement shall be deemed invalid or inoperative, or in the event a court of competent
jurisdiction determines that any of the provisions of this Agreement contravene public policy in any way, this Agreement shall be construed so that the remaining provisions shall not be affected, but shall remain in full force and effect, and any
such provisions which are invalid or inoperative or which contravene public policy shall be deemed, without further action or deed on the part of any person, to be modified, amended and/or limited, but only to the limited extent necessary to render
the same valid and enforceable, and the Company shall indemnify and hold harmless the Executive against Liabilities and reasonable Expenses with respect to any Action to the fullest extent permitted by any applicable provision of this Agreement that
shall not have been invalidated and otherwise to the fullest extent otherwise permitted by the Statute as it may then be in effect. 

  
 - 8 - 

 15. Certain Definitions. The following terms as used in this Agreement shall be
defined as follows: 
 A. “Action(s)” shall include, without limitation, any threatened, pending or completed action, claim,
litigation, suit or proceeding, whether civil, criminal, administrative, arbitrative or investigative, whether predicated on foreign, Federal, state or local law, whether brought under and/or predicated upon the Securities Act of 1933, as amended,
and/or the Securities Exchange Act of 1934, as amended, and/or their respective state counterparts and/or any rule or regulation promulgated thereunder, whether a Derivative Action and whether formal or informal. 

B. “Affiliate” shall include, without limitation, any corporation, partnership, joint venture, employee benefit plan, trust, or
other similar enterprise that directly or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the Company. 

C. “Authority” shall mean the panel of arbitrators or independent legal counsel selected under Paragraph 3C of the Agreement. 

D. “Beneficial Owner” has the meaning given to the term “beneficial owner” in
Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 

E. “Board” shall mean the Board of Directors of the Company. 

F. “Breach of Duty” shall mean the Executive breached or failed to perform his or her duties to the Company or an Affiliate, as the
case may be, and the Executive’s breach of or failure to perform those duties constitute: 
 (i) a breach of “Duty of
Loyalty” (as defined herein) to the Company or its stockholders; 
 (ii) acts or omissions not in “Good Faith” (as further
defined herein) or which involve intentional misconduct or a knowing violation of the law; 
 (iii) a violation of Section 174 of the
DGCL; or 
 (iv) a transaction from which the Executive derived an improper personal financial profit (unless such profit is determined to
be immaterial in light of all the circumstances). 
 In determining whether the Executive has acted or omitted to act otherwise than in “Good
Faith,” as such term is used herein, the Authority, or the court, shall determine solely whether the Executive (i) in the case of conduct in his or her “Official Capacity” (as defined herein) with the Company, believed in the
exercise of his or her business judgment, that his or her conduct was in the best interests of the Company; and (ii) in all other cases, reasonably believed that his or her conduct was at least not opposed to the best interests of the Company.

  
 - 9 - 

 G. “Change in Control” means the occurrence after the date of this Agreement of
any of the following events: 
 (i) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of
the Company representing 25% or more of the Company’s then outstanding Voting Securities unless the change in relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number
of outstanding shares of securities entitled to vote generally in the election of directors; 
 (ii) the consummation of a
reorganization, merger or consolidation, unless immediately following such reorganization, merger or consolidation, all of the Beneficial Owners of the Voting Securities of the Company immediately prior to such transaction beneficially own, directly
or indirectly, more than 50% of the combined voting power of the outstanding Voting Securities of the entity resulting from such transaction; 

(iii) during any period of two consecutive years, not including any period prior to the execution of this Agreement,
individuals who at the beginning of such period constituted the Board (including for this purpose any new directors whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved) cease for any reason
to constitute at least a majority of the Board; or 
 (iv) the stockholders of the Company approve a plan of complete
liquidation or dissolution of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 

H. “Derivative Action” shall mean any Action brought by or in the right of the Company and/or an Affiliate. 

I. “DGCL” shall mean the Delaware General Corporation Law. 

J. “Duty of Loyalty” shall mean a breach of fiduciary duty by the Executive which constitutes a willful failure to deal fairly with
the Company or its stockholders in connection with a transaction in which the Executive has a material undisclosed personal conflict of interest. 

K. “Expenses” shall include, without limitation, any and all expenses, fees, costs, charges, attorneys’ fees and disbursements,
other out-of-pocket costs, reasonable compensation for time spent by the Executive in connection with the Action for which he or she is not otherwise compensated by the
Company, any Affiliate, any third party or other entity, and any and all other direct and indirect costs of any type or nature whatsoever. 

L. “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither
presently performs, nor in the past five years has performed, services for either: (i) the Company or Executive (other than in connection with matters concerning Executive under this Agreement or of other indemnitees under similar agreements)
or (ii) any other party to the Action giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional
conduct then prevailing, would have a conflict of interest in representing either the Company or Executive in an action to determine Indemnitee’s rights under this Agreement. 

  
 - 10 - 

 M. “Liabilities” shall include, without limitation, judgments, amounts incurred in
settlement, fines, penalties, and, with respect to any employee benefit plan, any excise tax or penalty incurred in connection therewith, and any and all liabilities of every type or nature whatsoever. 

N. “Official Capacity” shall mean the office of director or officer in the Company, membership on any committee of directors, any
other offices in the Company held by the Executive and any other employment or agency relationship between the Executive and the Company and “Official Capacity,” as such term is used herein, shall not include service for any Affiliate or
other foreign or domestic corporation or any partnership, joint venture, trust, employee benefit plan, or other enterprise. 
 O.
“Person” means any individual, corporation, firm, partnership, joint venture, limited liability company, estate, trust, business association, organization, governmental entity or other entity and includes the meaning set forth in Sections
13(d) and 14(d) of the Exchange Act. 
 P. “Statute” shall mean DGCL Section 145 (or any successor provisions). 

Q. “Termination Date” shall mean the date the Executive ceases, for whatever reason, to serve as a director or officer the Company
and/or any Affiliate. 
 R. “Voting Securities” means any securities of the Company that vote generally in the election of
directors. 
 [Signature Page Follows] 

  
 - 11 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, all
as of the day and year first above written. 
  

			
	COMERA LIFE SCIENCES HOLDINGS, INC.
		
	By:	 	  

	Name: Jeffrey Hackman
	Its: Chief Executive Officer
	
	EXECUTIVE
	
	  

	Name:EX-10.12

 Exhibit 10.12 

SETTLEMENT AND RELEASE AGREEMENT 

This SETTLEMENT AND RELEASE AGREEMENT (this “Agreement”) is dated as of May 19, 2022, by and between OTR
Acquisition Corp. (together with its parents, subsidiaries and affiliates, “OTR”), Comera Life Sciences, Inc. (together with its parents, subsidiaries and affiliates, “Comera Life Sciences”), Comera Life Sciences
Holdings, Inc. (together with its parents, subsidiaries and affiliates, “Comera Life Sciences Holdings”) and Maxim Group LLC (together with its parents, subsidiaries and affiliates, “Maxim”). OTR, Comera Life
Sciences, Comera Life Sciences Holdings and Maxim are each sometimes referred to herein individually as a “Party” and together as the “Parties.” 

W I T N E S S E T H 

WHEREAS, on or around November 17, 2020, Maxim and OTR executed an underwriting agreement related to the initial public offering
of OTR (the “Underwriting Agreement”); 
 WHEREAS, pursuant to Section 1.3 of the Underwriting Agreement, Maxim
and OTR agreed that 3.25% of the gross proceeds from the sale of the Firm Units and the gross proceeds from the sale of the Option Units, for a total of $3,395,389 (the “Deferred Underwriting Commission”), was deposited in
and held in the Trust Account and would be payable directly from the Trust Account, without accrued interest, to Maxim for its own account upon consummation of the Business Combination1; 
 WHEREAS,
Maxim and Comera Life Sciences (formerly known as ReForm Biologics, Inc.) entered into an engagement agreement regarding the provision of advisory services, dated October 13, 2020, as amended and restated on or about August 16, 2021,
and as further amended on or about January 25, 2022 (the “Comera Advisory Agreement”);  
 WHEREAS, OTR
is in the process of consummating a Business Combination with Comera Life Sciences, Comera Life Sciences Holdings and other parties;  

WHEREAS, given the significant number of redemptions of OTR’s publicly traded shares in connection with the Business Combination,
OTR has informed Maxim that there are insufficient funds in the Trust Account to permit OTR to pay the Deferred Underwriting Commission; 
 WHEREAS,
Comera Life Sciences and Maxim desire to amend the terms of the Comera Advisory Agreement; and  
 WHEREAS, the Parties
wish to resolve certain disputes that have arisen or may arise between the Parties regarding their rights and obligations relating to the Deferred Underwriting Commission or Comera Advisory Agreement. 

 
  

	1	 Capitalized terms in this recital that are not otherwise defined herein shall have the meaning ascribed to them
in the Underwriting Agreement. 

 NOW THEREFORE, in consideration of the mutual promises herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto hereby agree as follows: 

1.    Consideration Relating to the Deferred Underwriting Commission. In lieu of the Deferred Underwriting
Commission that is owed to Maxim by OTR: 
  

	 	a.	 Comera Life Sciences Holdings shall, immediately prior to the closing of the Business Combination, issue to
Maxim Partners LLC shares of Series A Convertible Perpetual Preferred Stock (“Series A Preferred Shares”) in an amount equal in value to $3,395,389 (the “Maxim Preferred Underwriting Shares”), based on the
valuation (the “Valuation”) set forth in the Certificate of Designation for the Series A Preferred Shares included on Exhibit A hereto (the “Certificate of Designation”), which Maxim Preferred Underwriting Shares
shall have the rights, terms and conditions; set forth in the Certificate of Designation; and 

  

	 	b.	 The Maxim Preferred Underwriting Shares shall be held at the transfer agent of Comera Life Sciences Holdings,
Inc. in book entry in the name of Maxim Partners LLC as of the closing of the Business Combination. 

 In addition, Maxim hereby waives
the Right of First Refusal set forth in Section 3.32 of the Underwriting Agreement. 
 2.    Consideration
Relating to the Comera Advisory Agreement. In lieu of the Cash Fee that is owed to Maxim by Comera Life Sciences pursuant to the first paragraph of Section 3(B) of the Comera Advisory Agreement (and solely with respect to such Cash Fee),:

  

	 	a.	 Comera Life Sciences Holdings shall, immediately prior to the closing of the Business Combination, issue to
Maxim Partners LLC Series A Preferred Shares in an amount equal in value to $910,000 (i.e., the $1,000,000 Cash Fee less Retainer payments of $90,000) (the “Maxim Preferred Advisory Shares” and together with the “Maxim Preferred
Underwriting Shares, the “Maxim Partners Preferred Shares”), based on the Valuation, which Maxim Preferred Advisory Shares will have the rights, terms and conditions set forth in the Certificate of Designation; and 

 

	 	b.	 The Maxim Preferred Advisory Shares shall be held at the transfer agent of Comera Life Sciences Holdings in
book entry in the name of Maxim Partners LLC as of the closing of the Business Combination. 

 Notwithstanding anything
else contained in the Comera Advisory Agreement, each of Comera Life Sciences and Maxim hereby agrees that from and after the consummation of the Business Combination, Sections 3(B), 3(C) and 3(D) of the Comera Advisory Agreement shall only be
applicable with respect to a Transaction or Financing involving a counterparty that was introduced by Maxim to Comera Life Sciences prior to the date of this Agreement and set forth on Exhibit B attached hereto (each, a “Maxim
Party”) and, for the avoidance of doubt, (i) no additional Success Fee shall at any time be payable to Maxim by Comera Life Sciences or Comera Life 

  
 2 

 
Sciences Holdings pursuant to the Comera Advisory Agreement in connection with, and (ii) Maxim shall not have any other rights with respect to, any Transaction or Financing consummated at
any time following the closing of the Business Combination with a counterparty that is not a Maxim Party. For the sake of clarity, the contingency payment, milestone payment or deferred consideration Success Fee obligations in Section 3(B) with
respect to the Business Combination or any Transaction or Financing involving a Maxim Party are not affected by the foregoing. 

3.    Maxim Investment. Maxim Partners LLC (or an affiliate thereof) shall invest $1,000,000 via a private
placement in common stock of Comera Life Sciences Holdings (“Private Placement Shares”) at a price per share of $10.25 immediately prior to the closing of the Business Combination. In addition, the Private Placement Shares shall be
held at the transfer agent of Comera Life Sciences Holdings in book entry in the name of Maxim Partners LLC (or an affiliate) as of the closing of the Business Combination. In the event that the Business Combination is not consummated within
twenty-four hours of the receipt of the funds, any funds paid by Maxim in consideration of the Private Placement Shares shall be promptly returned to Maxim (to the same account from which it is received) within forty-eight hours of receipt. 

4.    Comera Advisory Agreement Amendment. The eighth, ninth and tenth sentences of Section 3(B) of the Comera
Advisory Agreement2 is hereby replaced with the following: 

The shares of Common Stock that comprise the Success Fee are registered pursuant to the approved Proxy/Registration Statement in connection
with the Closing of the Transaction. One hundred percent (100%) of such Common Stock shall be unrestricted and freely tradeable, and the Company shall immediately take all necessary steps to ensure that its transfer agent effects immediate delivery
of the unrestricted (“clean”) Common Stock to Maxim Partners LLC. 
 5.    Registration Rights. Comera
Life Sciences Holdings shall provide Maxim certain registration rights with respect to the Private Placement Shares and the common stock issuable upon conversion of the Maxim Partners Preferred Shares, as set forth in the registration rights
agreement among Comera Life Sciences Holdings and Maxim, dated the date hereof. 
  

 

	2	 For the sake of clarity, the sentences being replaced state: “The shares of Common Stock that comprise the
Success Fee will be registered in connection with the Closing of the Transaction, or if not so registered, Maxim shall be afforded demand and unlimited piggyback registration rights with respect to the Common Stock. Upon registration, fifty percent
(50%) of such Common Stock shall be unrestricted and freely tradeable, and the Company shall immediately take all necessary steps to ensure that its transfer agent effects immediate delivery of the unrestricted (“clean”) Common Stock to
Maxim Partners LLC. The fifty percent (50%) balance of the Common Stock shall be restricted until the earlier of (i) six (6) months from the Closing of the Transaction and (ii) the date following the Closing on which the Common Stock has a
closing price equal to or greater than $10.00 for five (5) of the preceding ten (10) trading days. Upon the occurrence of either event, the Company shall immediately take all necessary steps to ensure that its transfer agent effects
immediate delivery of the unrestricted (“clean”) Common Stock to Maxim Partners LLC.” 

  
 3 

 6.    Partial Release of OTR, Comera Life Sciences Holdings and
Comera Life Sciences. As of the issuance of Maxim Partners Preferred Shares, Maxim, for itself and any of its direct and indirect affiliates, parent corporations, subsidiaries, subdivisions, successors, predecessors, members, shareholders
and assigns (collectively, “Maxim Releasors”), hereby (a) releases, acquits and forever discharges OTR, Comera Life Sciences Holdings and Comera Life Sciences and each of their direct and indirect affiliates, parents,
subsidiaries, subdivisions, successors, predecessors, members, shareholders, and assigns, and their present and former officers, directors, legal representatives, employees, agents and attorneys, and their heirs, executors, administrators, trustees,
successors and assigns (the parties so released, herein each a “OTR/Comera Releasee” and collectively, the “OTR/Comera Releasees”) of and from any and all causes of actions, claims, suits, liens, losses, damages,
judgments, demands, liabilities, rights, obligations, costs, expenses, and attorneys’ fees of every nature, kind and description whatsoever, at law or in equity, whether individual, class or derivative in nature, whether based on federal, state
or foreign law or right of action, mature or unmatured, accrued or not accrued, known or unknown, fixed or contingent, which the Maxim Releasors ever had, now have or hereafter can, shall or may have against any of the OTR/Comera Releasees by reason
of any matter, cause or thing whatsoever arising out of Section 1.3 or Section 3.32 of the Underwriting Agreement, the Cash Fee set forth in Section 3(B) of the Comera Advisory Agreement (excluding the contingency payment, milestone
payment or deferred consideration Success Fee obligations with respect to the Business Combination), or Section 3(B), 3(C) or 3(D) of the Comera Advisory Agreement as relates to any Transaction or Financing that does not involve a Maxim Party
(excluding the contingency payment, milestone payment or deferred consideration Success Fee obligations with respect to the Business Combination) (collectively, the “OTR/Comera Released Claims”) and (b) covenants not to
institute, maintain or prosecute any action, claim, suit, complaint, proceeding or cause of action or any kind to enforce any of the OTR/Comera Released Claims, unless such claim relates to or arises from the OTR/Comera Releasee’s failure to
perform under this Agreement. In any litigation arising from or related to an alleged breach of this Section, this Agreement may be pleaded as a defense, counterclaim or crossclaim, and shall be admissible into evidence. Each Maxim Releasor
expressly covenants and agrees that the release granted by it in this Section shall be binding in all respects upon the Maxim Releasors and shall inure to the benefit of the successors and assigns of the OTR/Comera Releasees, and agrees that the
OTR/Comera Releasees shall have no further liabilities or obligations to Maxim Releasors under Section 1.3 or Section 3.32 of the Underwriting Agreement, with respect to the Cash Fee in Section 3(B) of the Comera Advisory Agreement
(excluding the contingency payment, milestone payment or deferred consideration Success Fee obligations with respect to the Business Combination), or Section 3(B), 3(C) or 3(D) of the Comera Advisory Agreement as relates to any Transaction or
Financing that does not involve a Maxim Party (excluding the contingency payment, milestone payment or deferred consideration Success Fee obligations with respect to the Business Combination), except as provided in this Agreement. Excluded from the
foregoing releases are any claims relating to or arising from the enforcement of this Agreement. 
 7.    Partial
Release of Maxim. As of the issuance of Maxim Partners Preferred Shares and the purchase of the Private Placement Shares, each of OTR, Comera Life Sciences Holdings and Comera Life Sciences, for themselves and each of their direct and
indirect affiliates, parent corporations, subsidiaries, subdivisions, successors, predecessors, members, shareholders and assigns (collectively the “OTR/Comera Releasors”), hereby (a) releases, acquits and forever discharges
Maxim and each of its direct and indirect affiliates, parents, subsidiaries, subdivisions, 

  
 4 

 
successors, predecessors, members, shareholders, and assigns, and their present and former officers, directors, legal representatives, employees, agents and attorneys, and their heirs, executors,
administrators, trustees, successors and assigns (the parties so released, herein each a “Maxim Releasee” and collectively, the “Maxim Releasees”) of and from any and all causes of actions, claims, suits, liens,
losses, damages, judgments, demands, liabilities, rights, obligations, costs, expenses, and attorneys’ fees of every nature, kind and description whatsoever, at law or in equity, whether individual, class or derivative in nature, whether based
on federal, state or foreign law or right of action, mature or unmatured, accrued or not accrued, known or unknown, fixed or contingent, which the OTR/Comera Releasors ever had, now have or hereafter can, shall or may have against any Maxim
Releasees by reason of any matter, cause or thing whatsoever arising under, related to Section 1.3 of the Underwriting Agreement or the Cash Fee set forth in Section 3(B) of the Comera Advisory Agreement (collectively, the “Maxim
Released Claims”) and (b) covenants not to institute, maintain or prosecute any action, claim, suit, complaint, proceeding or cause of action or any kind to enforce any of the Maxim Released Claims, unless such claim relates to or
arises from Maxim’s failure to perform under this Agreement. In any litigation arising from or related to an alleged breach of this Section, this Agreement may be pleaded as a defense, counterclaim or crossclaim, and shall be admissible into
evidence. Each OTR/Comera Releasor expressly covenants and agrees that the release granted by it in this Section shall be binding in all respects upon the OTR/Comera Releasors and shall inure to the benefit of the successors and assigns of the Maxim
Releasees, and agrees that the Maxim Releasees shall have no further liabilities or obligations to the OTR/Comera Releasors under Section 1.3 of the Underwriting Agreement or with respect to the Cash Fee in Section 3(B) of the Comera
Advisory Agreement, except as provided in this Agreement. Excluded from the foregoing releases are any claims relating to or arising from the enforcement of this Agreement. 

8.    Maxim Representations. Maxim represents and warrants that it is (i) an accredited investor,
(ii) has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Maxim Partners Preferred Shares and Private Placement Shares
(the “Securities”), and has so evaluated the merits and risks of such investment. Maxim is able to bear the economic risk of an investment in the Maxim Partners Preferred Shares and Private Placement Shares and, at the present time,
is able to afford a complete loss of such investment and (iii) it is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities (this representation and warranty not limiting Maxim’s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Maxim
understands that the Securities are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities hereunder in the ordinary course of its business. 

9.    Counterparts. This Agreement may be executed in any number of counterparts and by different Parties hereto on
separate counterparts, each of which counterparts, when executed and delivered, shall be deemed an original and all of which counterparts, taken together, shall constitute one and the same Agreement. A facsimile or PDF signature shall be deemed to
be an original signature for all purposes. 

  
 5 

 10.    Further Assurances. Each Party hereto agrees that, from
time to time, such Party will promptly execute and deliver all such further notices, instruments, consents and documents, and take all such further action, as may be reasonably necessary to effect the agreements of the Parties hereto set forth
herein. 
 11.    Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of each
Party hereto and its successors and assigns. The Parties acknowledge and agree that the Maxim Releasees and OTR/Comera Releasees are intended third party beneficiaries of this Agreement and that each of them may independently enforce the terms of
this Agreement just as if they were parties. 
 12.    Interpretation; Entire Agreement. This Agreement sets
forth the entire agreement and understanding among the Parties relating to the subject matter of this Agreement and all prior or contemporaneous agreements, understandings, representations and settlements, oral or written, relating to the subject
matter, are merged herein. This Agreement is not intended to, nor shall be deemed to, obviate, supersede or otherwise affect any terms of the Underwriting Agreement, the Comera Advisory Agreement or other agreements that may exist between the
Parties, except as specifically set forth herein. This Agreement may not be altered or amended except by a written instrument signed by all of the Parties. Any provision of this Agreement is found to be contrary to law or otherwise invalid, void or
unenforceable, it shall be deemed omitted but shall not affect the remaining terms of this Agreement, which shall remain in full force and effect. 

13.    Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of
the State of New York without regard to any law or principles that would make this choice of law provision invalid. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New
York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Each of the
parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit,
action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

14.    Authority. Each person whose signature is affixed hereto in a representative capacity represents and
warrants that he or she is authorized and empowered to execute this Agreement on behalf of, and to bind, the person or entity on whose behalf his or her signature is affixed, and the Parties hereto represent and warrant that they have all requisite
authority to enter into this agreement and effect the terms thereof. 
 [Signature Page Follows] 

  
 6 

 Intending to be legally bound hereby, the parties executed the foregoing Settlement and
Release Agreement this 19th day of May, 2022. 
  

			
	OTR ACQUISITION CORP.
		
	By:	 	 /s/ Nicholas J. Singer

	Name:	 	Nicholas J. Singer
	Title:	 	Chief Executive Officer
	
	COMERA LIFE SCIENCES HOLDINGS, INC.
		
	By:	 	 /s/ Jeffrey Hackman

	Name:	 	Jeffrey Hackman
	Title:	 	Chief Executive Officer
	
	COMERA LIFE SCIENCES, INC.
		
	By:	 	 /s/ Jeffrey Hackman

	Name:	 	Jeffrey Hackman
	Title:	 	Chief Executive Officer
	
	MAXIM GROUP LLC
		
	By:	 	 /s/ Clifford Teller

	Name:	 	Clifford Teller
	Title:	 	Co-President

  
 7 

 Exhibit A 

Certificate of Designation 

  
 8 

 CERTIFICATE OF DESIGNATION 

OF 
 SERIES A CONVERTIBLE
PERPETUAL PREFERRED STOCK 
 OF 

COMERA LIFE SCIENCES HOLDINGS, INC. 

(Pursuant to Section 151 of the General Corporation Law of the State of Delaware) 

Comera Life Sciences Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware
(hereinafter, the “Corporation”), hereby certifies that: 
 1.    This Certificate of Designation of
Series A Convertible Perpetual Preferred Stock shall be effective at 1:01 p.m. Eastern time on May 19, 2022. 

2.    The following resolution was duly adopted by the Board of Directors of the Corporation (or a duly authorized
committee thereof) as required by Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”): 

“NOW, THEREFORE, BE IT RESOLVED, that pursuant to the authority expressly granted to and vested in the Board of Directors of the
Corporation in accordance with the provisions of the certificate of incorporation of the Corporation, there is hereby created and provided out of the authorized but unissued preferred stock, par value $0.0001 per share, of the Corporation
(“Preferred Stock”), a new series of Preferred Stock, and there is hereby established and fixed the number of shares included such series, the voting powers, full or limited, or that such series shall have no voting powers, and, the
designations, powers, preferences and relative, participating, optional, special and other rights, if any, of such series and the qualifications, limitations and restrictions, if any, of such series as follows: 

Series A Convertible Perpetual Preferred Stock: 

Section 1.    Designation and Number. The shares of such series shall be designated as “Series A
Convertible Perpetual Preferred Stock,” par value $0.0001 per share, of the Corporation (the “Series A Preferred Stock”), and the number of shares constituting such series shall be Four Thousand Three Hundred and Five
(4,305). 
 Section 2.    Definitions. The following terms shall have the following meanings for
purposes of this Certificate of Designation (as the same may be amended or amended and restated from time to time, this “Certificate of Designation”): 

(a)    “Additional Shares of Common Stock” shall mean all shares of Common Stock issued other than:
(i) shares of Common Stock issued upon conversion of Series A Preferred Stock pursuant to Section 7; (ii) shares of Common Stock issued upon conversion, exchange or exercise of Common Stock Equivalents;
(iii) shares of Common Stock issued upon a split or a combination or a reclassification or recapitalization of outstanding shares of Common Stock, in each case, as provided in Section 8(a) - (c), liquidation,
dissolution or winding up of the Corporation, a Qualifying Merger or a Qualifying Sale; and (iv) shares of Common Stock issued to employees or directors of, or consultants to, the Corporation or any of its subsidiaries pursuant to a
plan, agreement or arrangement approved by the Board of Directors. 

 (b)    “Average Price” shall mean, in respect of shares
of Common Stock or any other securities, as of any day or relevant period (as applicable): (i) the volume weighted average price for such shares or securities on a National Securities Exchange for such day or relevant period (as applicable) as
reported by Bloomberg Finance Markets (“Bloomberg”) through its “Volume at Price” functions; (ii) if, as determined by the Board of Directors, a National Securities Exchange is not the principal securities
exchange or trading market for such shares or securities, the volume weighted average of such shares or securities for such day or relevant period (as applicable) on the securities exchange or trading market for such shares or securities determined
by the Board of Directors to be the principal securities exchange or trading market for such shares or securities as reported by Bloomberg through its “Volume Price” functions; (iii) if the foregoing clauses (i) and (ii)
do not apply, the last closing trading price for such day or the average of the last closing trading prices for such relevant period (as applicable) of such shares or securities in the
over-the-counter market on the electronic bulletin board for such shares or securities as reported by Bloomberg; (iv) if the forgoing clauses (i) and
(ii) do not apply, and no last closing trade price for such day or relevant period (as applicable) is reported by Bloomberg, the last closing ask price for such day or the average of the last closing ask prices for such relevant period (as
applicable) of such shares or securities as reported by Bloomberg; or (v) if the forgoing clauses (i) – (iv) do not apply, the fair market value of such share or security for such day or relevant period (as applicable) as
determined by the Board of Directors. 
 (c)    “Board of Directors” shall mean the Board of Directors
of the Corporation. 
 (d)    “Certificate of Incorporation” shall mean the certificate of
incorporation of the Corporation (including any certificate filed with the Secretary of State of the State of Delaware establishing a series of Preferred Stock), as the same may be amended or amended and restated. 

(e)    “Common Stock” shall mean the common stock, par value $0.0001 per share, of the Corporation. 

(f)    “Common Stock Equivalents” shall mean securities convertible into, or entitling the holder to
receive, directly or indirectly, shares of Common Stock or rights, options or warrants to subscribe for, purchase or otherwise acquire shares of Common Stock other than such securities or rights, options or warrants issued: (i) on or prior to
the Series A Original Issue Date; and (ii) to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors. 

(g)    “Equity Financing” shall mean any transaction occurring after the Series A Original Issue Date
involving the issuance or sale of Additional Shares of Common Stock or Common Stock Equivalents, including, without limitation, pursuant to an equity line of credit facility, a registered offering, a private investment in public equity or otherwise;
“Equity Financings” means more than one of such transactions. 
 (h)    “Liquidation
Proceeds” shall have the meaning set forth in Section 4(a). 

  
 2 

 (i)    “National Securities Exchange” shall mean the
Nasdaq Stock Market, the New York Stock Exchange or any other national securities exchange. 
 (j)    “public
announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange
Commission pursuant to Section 13, 14, and 15(d) (or any successor thereto) of the Securities Exchange Act of 1934, as amended. 

(k)    “Qualifying Financing Event” shall mean the last closing of one or more Equity Financings
resulting in aggregate proceeds to the Corporation (after deductions for fees, costs and expenses actually incurred by the Corporation in connection therewith) of $5,000,000.00. 

(l)    “Qualifying Financing Period” shall have the meaning set forth in
Section 12(a). 
 (m)    “Qualifying Financing Proceeds” shall mean thirty
percent (30%) of the proceeds to the Corporation (after deduction for fees, costs and expenses actually incurred by the Corporation in connection therewith) from any one or more Equity Financings in excess of $5,000,000.00. 

(n)    “Qualifying Merger” shall mean: (i) a merger or consolidation to which the Corporation is a
constituent entity and which results in fifty percent (50%) or more of the capital stock or similar equity interest of the surviving, resulting or consolidated entity or fifty percent (50%) or more of the voting power of the capital stock or similar
equity interest of the surviving, resulting or consolidated entity, in either case, being held by persons and/or entities other than the persons and/or entities that, immediately prior to the effective time of such merger or consolidation, owned
fifty percent (50%) or more of the capital stock of the Corporation or fifty percent (50%) or more the voting power of the capital stock of the Corporation; or (ii) a merger or consolidation to which any one or more of the Corporation’s
subsidiaries is a constituent entity and which results in fifty percent (50%) or more of the capital stock of the Corporation or fifty percent (50%) or more of the voting power of the capital stock of the Corporation, in either case, being held by
persons and/or entities other than the persons and/or entities that, immediately prior to the effective time of such merger or consolidation, owned fifty percent (50%) or more of the capital stock of the Corporation or fifty percent (50%) or more of
the voting power of the capital stock of the Corporation. 
 (o)    “Qualifying Merger Consideration”
shall have the meaning set forth in Section 4(b). 
 (p)    “Qualifying Sale” shall
mean any sale, lease or exchange of all or substantially all of the property and assets of the Corporation, including its goodwill and its corporate franchises. For purposes of this definition of Qualifying Sale only, the property and assets of the
Corporation shall include the property and assets of any subsidiary (as defined in Section 271(c) of the DGCL) of the Corporation. 

(q)    “Qualifying Sale Consideration” shall have the meaning set forth in
Section 4(c). 
 (r)    “Securities Act” means the Securities Act of 1933, as
amended. 

  
 3 

 (s)    “Series A Conversion Price” shall mean $12.56,
as adjusted pursuant to Section 8. 
 (t)    “Series A Corporation Redemption Date”
shall have the meaning set forth in Section 11(a). 
 (u)    “Series A Dividend Junior
Stock” shall mean the Common Stock and any outstanding series of Preferred Stock provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking junior to the Series A Preferred Stock as to dividends. 

(v)    “Series A Dividend Parity Stock” shall mean any outstanding series of Preferred Stock provided for
or fixed pursuant to the provisions of the Certificate of Incorporation ranking pari passu to the Series A Preferred Stock as to dividends. As of the Series A Original Issue Date, there is no Series A Dividend Parity Stock. 

(w)    “Series A Dividend Rate” shall mean, for each outstanding share of Series A Preferred Stock, eight
percent (8.0%) per annum on the Series A Preference Price for the first six Series A Quarterly Dividend Payment Dates following the Series A Original Issue Date, which such Series A Dividend Rate shall increase by two percent (2.0%) per annum on the
Series A Preference Price from and after each successive Series A Quarterly Dividend Payment Date following such first six Series A Quarterly Dividend Payment Dates, up to a maximum of eighteen percent (18.0%) per annum on the Series A Preference
Price; provided, however, that if there is a Series A Dividend Rate Modifier, the Series A Dividend Rate shall automatically be increased to the maximum of eighteen percent (18.0%). 

(x)    “Series A Dividend Rate Modifier” shall mean the occurrence of any one or more of the following:
(i) The Corporation shall have failed to issue and deliver a certificate or certificates representing the number of whole shares of Common Stock and cash in lieu of fractional shares of Common Stock to which a holder shall be entitled to
Section 7(c); (ii) The Corporation shall have failed to make any adjustment or readjustment of the Series A Conversion Price pursuant to Section 8; (iii) The Corporation shall have failed to
reserve and keep available out of its authorized but unissued shares of Series A Preferred Stock then outstanding, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all shares of Series A
Preferred Stock then outstanding; (iv) The Corporation shall have failed to deliver the Series A Redemption Price, in cash, to the holders of shares of Series A Preferred Stock entitled thereto pursuant to
Section 11(c); and (v) The Corporation shall have failed to deliver the Series A Redemption Price, in cash, to the holders of Series A Preferred Stock entitled thereto pursuant to
Section 12(d). 
 (y)    “Series A Dividend Senior Stock” shall mean any
outstanding series of Preferred Stock provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking senior to the Series A Preferred Stock as to dividends. As of the Series A Original Issue Date, there is no Series A
Dividend Senior Stock. 
 (z)    “Series A Liquidation Junior Stock” shall mean the Common Stock and
any outstanding series of Preferred Stock provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking junior to the Series A Preferred Stock as to a liquidation, dissolution or winding up of the Corporation. 

  
 4 

 (aa)    “Series A Liquidation Parity Stock” shall mean
any outstanding series of Preferred Stock provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking on parity with the Series A Preferred Stock as to a liquidation, dissolution or winding up of the Corporation. As
of the Series A Original Issue Date, there is no Series A Liquidation Parity Stock. 
 (bb)    “Series A
Liquidation Senior Stock” shall mean any outstanding series of Preferred Stock provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking senior to the Series A Preferred Stock as to a liquidation,
dissolution or winding up of the Corporation. As of the Series A Original Issue Date, there is no Series A Liquidation Senior Stock. 

(cc)    “Series A Optional Conversion Date” shall have the meaning set forth in
Section 7(b). 
 (dd)    “Series A Optional Redemption Date” shall have the meaning
set forth in Section 12(d). 
 (ee)    “Series A Original Issue Date” shall mean the
date of the first issuance of any share or shares of Series A Preferred Stock. 
 (ff)    “Series A Original
Purchase Price” shall mean $1,000.00 per share of Series A Preferred Stock. 
 (gg)    “Series A
Preference Price” shall mean, with respect to an outstanding share of Series A Preferred Stock, the Series A Original Purchase Price (as adjusted for any split or subdivision of outstanding shares of Series A Preferred Stock, any
combination of outstanding shares of Series A Preferred Stock or a reclassification or recapitalization of outstanding shares of Series A Preferred Stock (other than a split or subdivision or combination), in each case, occurring after the Series A
Original Issue Date), plus the aggregate amount of dividends then accrued on such share of Series A Preferred Stock. 

(hh)    Series A Qualifying Merger Junior Stock” shall mean the Common Stock and any outstanding series of
Preferred Stock provided for a fixed pursuant to the provisions of the Certificate of Incorporation ranking junior to the Series A Preferred Stock as to a Qualifying Merger. 

(ii)    “Series A Qualifying Merger Parity Stock” shall mean any outstanding series of Preferred Stock
provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking on parity with the Series A Preferred Stock as to a Qualifying Merger. As of the Series A Original Issue Date, there is no Series A Qualifying Merger Parity
Stock. 
 (jj)    “Series A Qualifying Merger Senior Stock” shall mean any outstanding series of
Preferred Stock provided or fixed pursuant to the provisions of the Certificate of Incorporation ranking senior to the Series A Preferred Stock as to a Qualifying Merger. As of the Series A Original Issue Date, there is no Series A Qualifying Merger
Senior Stock. 

  
 5 

 (kk)    “Series A Qualifying Sale Junior Stock” shall
mean the Common Stock and any outstanding series of Preferred Stock provided for a fixed pursuant to the provisions of the Certificate of Incorporation ranking junior to the Series A Preferred Stock as to a Qualifying Sale. 

(ll)    “Series A Qualifying Sale Parity Stock” shall mean any outstanding series of Preferred Stock
provided for or fixed pursuant to the provisions of the Certificate of Incorporation ranking on parity with the Series A Preferred Stock as to a Qualifying Sale. As of the Series A Original Issue Date, there is a Series A Qualifying Sale Parity
Stock. 
 (mm)    “Series A Qualifying Sale Senior Stock” shall mean any outstanding series of
Preferred Stock provided or fixed pursuant to the provisions of the Certificate of Incorporation ranking senior to the Series A Preferred Stock as to a Qualifying Merger. As of the Series A Original Issue Date, there is no Series A Qualifying Sale
Senior Stock. 
 (nn)    “Series A Quarterly Dividend Payment Date” shall have the meaning set forth in
Section 3(a). 
 (oo)    “Series A Redemption Price” shall mean, with respect
to an outstanding share of Series A Preferred Stock, (i) the Series A Original Purchase Price (as adjusted for any split or subdivision of outstanding shares of Series A Preferred Stock, any combination of outstanding shares of Series A
Preferred Stock or a reclassification or recapitalization of outstanding shares of Series A Preferred Stock (other than a split or subdivision or combination), in each case, occurring after the Series A Original Issue Date), plus
(ii) the aggregate amount of dividends then accrued on such share of Series A Preferred Stock, in each case, determined as of the Series A Corporation Redemption Date or the Series A Optional Redemption Date, as applicable. 

(pp)    “Trading Day” shall mean any day on which the National Securities Exchange is open for business
(other than a day on which the National Securities Exchange is scheduled to or does close prior to its regular weekday closing time). 
 Unless the context
otherwise requires: (i) the word “or” is not exclusive; (ii) the words “including” or “includes” shall be deemed to be following by “without limitation”; (iii) words in the singular include the
plural and in the plural include the singular; and (iv) the words “herein,” “hereof” and “hereunder” or words of similar import refer to this Certificate of Designation as a whole and not to a particular Section,
subsection or clause of this Certificate of Designation. 
 Section 3.    Dividends. 

(a)    Preferential Dividends. Subject to the rights of the holders of any Series A Dividend Senior Stock, for so
long as any shares of Series A Preferred Stock shall be outstanding, the holders of outstanding shares of Series A Preferred Stock shall be entitled to receive, except to the extent prohibited by Delaware law governing distributions to stockholders,
prior and in preference to the declaration or payment of any dividend on any Series A Dividend Junior Stock, and on a pari passu basis with respect to the declaration or payment of any dividend on any Series A Dividend Parity Stock,
dividends when, as and if declared by the Board of Directors, payable quarterly on January 1, April 1, July 1 and October 1 of each calendar year (provided, however, that if such date is not a business day,
the relevant quarterly dividend shall be payable on the first business day following such date) (each date a “Series A Quarterly Dividend Payment Date”), 

  
 6 

 
commencing on and including July 1, 2022, which dividends shall be paid in cash at the Series A Dividend Rate. Such dividends shall cumulate quarterly at the Series A Dividend Rate if not
declared and paid on a Series A Quarterly Dividend Payment Date. If the dividend to be distributed among the holders of outstanding shares of Series A Preferred Stock and Series A Dividend Parity Stock shall be insufficient to permit the payment to
such holders of the full aforesaid preferential amounts, then the entire amount available for distribution under Delaware law governing distributions to stockholders shall be distributed ratably among the holders of outstanding shares of Series A
Preferred Stock and Series A Dividend Parity Stock in proportion to the full preferential amount that each such holder is otherwise entitled to receive. 

(b)     Dividends in Excess of Preferential Dividends. The holders of outstanding shares of Series A Preferred
Stock shall not be entitled to the declaration and payment of any dividend in excess of full cumulative dividends on the Series A Preferred Stock as provided in this Section 3. 

Section 4.    Liquidation, Dissolution or Winding Up; Qualifying Merger; Qualifying Sale. 

(a)    Liquidation, Dissolution or Winding Up. Subject to the rights of the holders of any Series A Liquidation
Senior Stock, in the event of the Corporation’s liquidation, dissolution or winding up, the holders of outstanding shares of Series A Preferred Stock shall be entitled to receive, out of the assets of the Corporation available for distribution
to the Corporation’s stockholders (the “Liquidation Proceeds”), prior and in preference to any distribution of the Liquidation Proceeds to the holders of any Series A Liquidation Junior Stock, and on a pari passu
basis with respect to the holders of any Series A Liquidation Parity Stock, consideration in an amount per share equal to the Series A Preference Price. If, upon the occurrence of a liquidation, dissolution or winding up of the Corporation, the
Liquidation Proceeds distributed among the holders of outstanding shares of Series A Preferred Stock and any Series A Liquidation Parity Stock shall be insufficient to permit the payment to such holders of the full preferential amounts to which they
are entitled, then the entire Liquidation Proceeds shall be distributed ratably among the holders of outstanding shares of Series A Preferred Stock and such Series A Liquidation Parity Stock in proportion to the full preferential amount to which
each such holder is otherwise entitled to receive. In the event of the Corporation’s liquidation, dissolution or winding up, after payment in full of the amounts to which they are entitled pursuant to this
Section 4(a), the holders of Series A Preferred Stock shall not be entitled to any further right or claim to any of the remaining Liquidation Proceeds. A Qualifying Merger, a Qualifying Sale, a merger or consolidation of
the Corporation with or into another corporation or other entity or sale of all or any part of the assets of the Corporation which, in each case, shall not in fact result in the liquidation, dissolution or winding up of the Corporation and the
distribution of its assets to its stockholders, shall not be deemed a liquidation, dissolution or winding up of the Corporation within the meaning of this Section 4(a). 

(b)    Qualifying Merger. Subject to the rights of the holders of any Series A Qualifying Merger Senior Stock, in
the event of a Qualifying Merger, the holders of outstanding shares of Series A Preferred Stock shall be entitled to receive, in connection with the conversion in the Qualifying Merger of the shares of Series A Preferred Stock held by them
immediately prior to the effectiveness of the Qualifying Merger, out of the aggregate consideration to which the holders of all capital stock of the Corporation are entitled to receive in connection with the conversion in the

  
 7 

 
Qualifying Merger of such shares held by them immediately prior to the effectiveness of the Qualifying Merger (the “Qualifying Merger Consideration”), prior and in preference to
the receipt of Qualifying Merger Consideration by the holders of any Series A Qualifying Merger Junior Stock, and on a pari passu basis with the receipt of Qualifying Merger Consideration by the holders of any Series A Qualifying
Merger Parity Stock, consideration in an amount per share equal to the Series A Preference Price. If, upon the occurrence of a Qualifying Merger, the Qualifying Merger Consideration distributed among the holders of outstanding shares of Series A
Preferred Stock and any Series A Qualifying Merger Parity Stock shall be insufficient to permit the payment to such holders of the full preferential amounts to which they are entitled to receive, then the entire Qualifying Merger Consideration shall
be distributed ratably among the holders of outstanding shares of Series A Preferred Stock and such Series A Qualifying Merger Parity Stock in proportion to the full preferential amount to which each such holder is otherwise entitled to receive. In
the event of a Qualifying Merger, after payment in full of the amounts to which they are entitled pursuant to this Section 4(b), the holders of Series A Preferred Stock shall not be entitled to any further right or claim to
any of the remaining Qualifying Merger Consideration. 
 (c)    Qualifying Sale. Subject to the rights of the
holders of any Series A Qualifying Sale Senior Stock, in the event of a Qualifying Sale, the holders of outstanding shares of Series A Preferred Stock shall be entitled to be paid, out of the aggregate consideration payable to the Corporation in
such Qualifying Sale (the “Qualifying Sale Consideration”), prior and in preference to the payment, out of the Qualifying Sale Consideration, to holders of any Series A Qualifying Sale Junior Stock, and on a pari passu
basis with the payment, out of the Qualifying Sale Consideration, to the holders of any Series A Qualifying Sale Parity Stock, consideration in an amount per share equal to the Series A Preference Price. Subject to the rights of the holders of any
Series A Qualifying Sale Senior Stock, in the event of a Qualifying Sale, the Corporation shall apply all of the Qualifying Sale Consideration available for distribution under Delaware law governing distributions to stockholders to the payment of
the Series A Preference Price to all holders of outstanding shares of Series A Preferred Stock, and to no other corporate purpose or purposes to the fullest extent permitted by applicable law. If, upon the occurrence of a Qualifying Sale, the
Qualifying Sale Consideration thus distributed among the holders of outstanding shares of Series A Preferred Stock and any Series A Qualifying Sale Parity Stock shall be insufficient to permit the payment to such holders of the full preferential
amounts to which they are entitled to receive, then the entire Qualifying Sale Consideration shall be distributed ratably among the holders of outstanding shares of Series A Preferred Stock and such Series A Qualifying Sale Parity Stock in
proportion to the full preferential amount to which each such holder is otherwise entitled to receive. In the event of a Qualifying Sale, after payment in full of the amounts to which they are entitled pursuant to this
Section 4(c), the holders of Series A Preferred Stock shall not be entitled to any further right or claim to any of the remaining Qualifying Sale Consideration. 

(d)    Determining Liquidation Proceeds, Qualifying Merger Consideration and Qualifying Sale Consideration.
In the event of a liquidation, dissolution or winding up of the Corporation, a Qualifying Merger or a Qualifying Sale, if any of the Liquidation Proceeds, the Qualifying Merger Consideration or the Qualifying Sale Consideration, respectively, is in
a form 

  
 8 

 
other than cash, its value for purposes of applying the terms of Section 4(a), Section 4(b) and Section 4(c),
respectively, shall be the fair market value thereof determined as follows: 
 (i)    Securities shall be valued at the
Average Price of such securities over the twenty (20) Trading Day period ending three (3) Trading Days prior to the distribution date (in the event of a liquidation, dissolution or winding up the Corporation) or the closing date (in the
event of a Qualifying Merger or a Qualifying Sale), as applicable; 
 (ii)    Any consideration other than cash or
securities shall be valued by the Board of Directors; and 
 (iii)    The foregoing methods for valuing consideration
other than cash to be distributed in connection with a Qualifying Merger or a Qualifying Sale, as applicable, may be superseded by any determination of such value set forth in the definitive agreements governing such Qualifying Merger or a
Qualifying Sale, respectively. 
 (e)    Noncompliance. In the event the requirements of this
Section 4 are not complied with, to the fullest extent permitted by applicable law, the Corporation shall forthwith either: 

(i)    Cause the closing of such Qualifying Merger or such Qualifying Sale, as applicable, to be postponed or delayed
until such time as the requirements of this Section 4 have been complied with; or 

(ii)    Terminate or abandon such Qualifying Merger or such Qualifying Sale, as applicable, in which event (for the
avoidance of doubt) the voting powers, if any, and the preferences and relative, participating, optional or other special rights, if any, and the qualifications, limitations or restrictions, if any, of Series A Preferred Stock shall, to the fullest
extent permitted by applicable law, be the same as or revert to, as applicable, voting powers, if any, and the preferences and relative, participating, optional, special or other rights, if any, and the qualifications, limitations or restrictions,
if any, existing prior to such Qualifying Merger or such Qualifying Sale, respectively. 

Section 5.    Voting. 

(a)    General. Except as provided by the Certificate of Incorporation or applicable law, each holder of a share of
Series A Preferred Stock, as such, shall be entitled to cast the number of votes equal to the number of shares of Common Stock into which such share of Series A Preferred Stock could be converted pursuant to Section 7 (as
of the record date for determining the stockholders entitled to vote) on all matters on which stockholders are generally entitled to vote; provided, however, to the fullest extent permitted by applicable law, in no event shall the
holders of outstanding shares of Series A Preferred Stock be entitled to cast a number of votes exceeding, in the aggregate, 19.99% of the voting power of the then outstanding shares of capital stock of the Corporation (which, for the avoidance of
doubt, shall include the Series A Preferred Stock). 
 (b)    Protective Provisions. For so long as any shares of
Series A Preferred Stock shall be outstanding, the Corporation shall not, directly or indirectly, by amendment, merger, consolidation or otherwise, without (in addition to any other vote required by the Certificate of Incorporation or applicable
law) the prior vote or consent of the holders of at least ninety percent (90%) of the then outstanding shares of Series A Preferred Stock, voting or consenting separately as a single class, and any such act or transaction entered into without such
vote or consent shall, 

  
 9 

 
to the fullest extent permitted by applicable law, be null and void ab initio, and of no force or effect: 

(i)    Amend, alter or repeal any provision of the Certificate of Incorporation or this Certificate of Designation if such
amendment, alteration or repeal would alter or change the powers, preferences or special rights of the shares of Series A Preferred Stock so as to affect them adversely; 

(ii)    Create, or authorize the creation of, or issue any series of Preferred Stock, or reclassify any class or series of
capital stock into any series of Preferred Stock; 
 (iii)    Purchase or redeem, or permit any subsidiary of the
Corporation to purchase or redeem, any shares of any Series A Dividend Junior Stock, Series A Liquidation Junior Stock, Series A Qualifying Merger Junior Stock or Series A Qualifying Sale Junior Stock, other than repurchases of shares of such
capital stock from former directors, officers, employees, consultants or other persons performing services for the Corporation or any subsidiary of the Corporation in connection with the cessation of employment or service and for a purchase price
per share of such capital stock not exceeding the original purchase price thereof; 
 (iv)    Incur, or permit the
Corporation’s subsidiaries to incur, or issue, or permit the Corporation’s subsidiaries to issue, any indebtedness for borrowed money, including obligations (whether or not contingent), under guaranties, or loans or debt securities,
including equity-linked or convertible debt securities; 
 (v)    Declare or pay any dividend on any Series A Dividend
Junior Stock; or 
 (vi)    Enter into, or permit the Corporation’s subsidiaries to enter into, any agreement,
arrangement or understanding providing for any of the actions described in the aforesaid clauses (i) - (v). 

Section 6.    Intentionally Omitted. 

Section 7.    Optional Conversion. 

(a)    Optional Conversion. Each outstanding share of Series A Preferred Stock may be converted into such number of
fully paid and nonassessable shares of Common Stock as determined by dividing the Series A Original Purchase Price by the Series A Conversion Price at any time or time to time by the holder thereof pursuant to this
Section 7; provided, however, in no event shall outstanding shares of Series A Preferred Stock be converted into more than 19.99% of the outstanding shares of Common Stock. 

(b)    Mechanics of Optional Conversion. Any holder of an outstanding share or shares of Series A Preferred Stock
desiring to convert such share or shares into shares of Common Stock pursuant to this Section 7(b) shall deliver (on a business day) written notice thereof to the principal office of the Corporation or of any transfer agent
for Series A Preferred Stock specifying the number of outstanding shares of Series A Preferred Stock held by such holder proposed to be converted (if such notice is silent as to the number of outstanding shares of Series A Preferred Stock held by
the holder and proposed to be converted pursuant to this Section 7(b), the notice 

  
 10 

 
shall be deemed to apply to all outstanding shares of Series A Preferred Stock held by such holder), together with the certificate or certificates representing the outstanding share or shares of
Series A Preferred Stock proposed to be converted under this Section 7(b), duly indorsed for transfer to the Corporation (the business day on which such written notice and certificate or certificates are delivered to the
Corporation as provided in this Section 7(b), the “Series A Optional Conversion Date”).  

(c)    Delivery of Shares of Common Stock. The Corporation shall, as soon as practicable, and in no event later
than three (3) Trading Days after the Series A Optional Conversion Date, issue and deliver to such holder of Series A Preferred Stock, or the nominee or nominees of such holder, a certificate or certificates representing the number of whole
shares of Common Stock to which such holder shall be entitled pursuant to Section 7(a) and cash in lieu of any fractional shares of Common Stock to which such holder is entitled pursuant to
Section 7(a), and the certificate or certificates representing the share or shares of Series A Preferred Stock so surrendered shall be cancelled. In the event that there shall have been surrendered a certificate or
certificates representing shares of Series A Preferred Stock, only a portion of shall have been converted pursuant to this Section 7, then the Corporation shall also issue and deliver to such holder, or the nominee or
nominees of such holder, a certificate or certificates representing the number of shares of Series A Preferred Stock which shall not have been converted pursuant to this Section 7. 

(d)    Effect of Conversion. Any conversion pursuant to this Section 7 shall be deemed to
have been made immediately prior to the close of business on the Series A Optional Conversion Date and (i) the voting powers, if any, and the preferences and relative, participating, optional, special or other rights, if any, and the
qualifications, limitations or restrictions, if any, of Series A Preferred Stock existing immediately prior to such time shall terminate and (ii) the person or persons entitled to receive a certificate or certificates representing shares of
Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of immediately prior to the close of business on the Series A Optional Conversion Date. 

Section 8.    Series A Conversion Price Adjustments. The Series A Conversion Price shall be subject to
adjustment from time to time after the Series A Original Issue Date as follows: 
 (a)    Split or Subdivision of
Common Stock. In the event that, at any time or from time to time after the Series A Original Issue Date, a record date is fixed for the effectuation of a split or subdivision of outstanding shares of Common Stock, then, as of such record date,
the Series A Conversion Price shall be appropriately decreased so that the number of shares of Common Stock issuable on conversion of each share of Series A Preferred Stock shall be increased in proportion to such increase of the aggregate number of
shares of Common Stock outstanding. 
 (b)    Combination of Common Stock. In the event that, at any time or from
time to time after the Series A Original Issue Date, a record date is fixed for the effectuation of a combination of outstanding shares of Common Stock, then, as of such record date, the Series A Conversion Price shall be appropriately increased so
that the number of shares of Common Stock issuable on conversion of each share of Series A Preferred Stock shall be decreased in proportion to such decrease in outstanding shares of Common Stock. 

  
 11 

 (c)    Reclassification or Recapitalization of Common Stock. In
the event that, at any time or from time to time after the Series A Original Issue Date, there shall be a reclassification or recapitalization of outstanding shares of Common Stock (other than a split or subdivision provided for
Section 8(a)., a combination provided for in Section 8(b), a liquidation, dissolution or winding up of the Corporation, a Qualifying Merger or a Qualifying Sale), to the fullest extent permitted by applicable
law, provision shall be made so that the holders of Series A Preferred Stock shall thereafter be entitled to receive upon conversion of Series A Preferred Stock the number of shares of stock or other securities or property of the Corporation or
otherwise, to which a holder of Common Stock deliverable upon conversion would have been entitled on such reclassification or recapitalization. In any such case, appropriate adjustment shall, to the fullest extent permitted by applicable law, be
made in the application of the provisions of this Section 8(c) with respect to the rights of the holders of Series A Preferred Stock after the reclassification or recapitalization to the end that the provisions of this
Section 8(c) (including adjustment of the Series A Conversion Price then in effect and the number of shares received upon conversion of Series A Preferred Stock) shall be applicable after that event as nearly equivalently
as may be practicable. The provisions of this Section 8(c) shall similarly apply to successive qualifying reclassifications or recapitalizations of outstanding shares of Common Stock (other than a split or subdivision
provided for in Section 8(a)., a combination provided for in Section 8(b), a liquidation, dissolution or winding up of the Corporation, a Qualifying Merger or a Qualifying Sale). 

(d)    Certificate as to Adjustments. The Corporation shall, upon the written request delivered to the Corporation
at the principal office of the Corporation at any time by any holder of Series A Preferred Stock, furnish or cause to be furnished to such holder a certificate setting forth (i) each adjustment and readjustment of the Series A Conversion Price
made pursuant to this Section 8, (ii) the Series A Conversion Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other property that at the time would be received upon
the conversion of a share of Series A Preferred Stock pursuant to Section 7. 

Section 9.    Reservation of Common Stock Issuable Upon Conversion. The Corporation shall at all times reserve
and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of outstanding shares of Series A Preferred Stock pursuant to Section 7, such number of shares
of Common Stock as shall from time to time be sufficient to effect the conversion of three hundred percent (300%) of all shares of Series A Preferred Stock then outstanding; and if at any time the number of authorized but unissued shares of Common
Stock shall not be sufficient to effect the conversion of three hundred percent (300%) of all shares of Series A Preferred Stock then outstanding pursuant to Section 7 then, in addition to such other remedies as shall be
available to the holders of Series A Preferred Stock, the Corporation shall, to the fullest extent permitted by applicable law, take such corporate action as may, in the opinion of its counsel, be necessary to increase the total number of authorized
shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of
Incorporation. 

  
 12 

 Section 10.    Notices. Any notice required by the
provisions of this Certificate of Designation to be given to a holder or holders of outstanding shares of Series A Preferred Stock shall be deemed given to each holder of record in any manner permitted under the DGCL. 

Section 11.    Redemption at the Option of the Corporation. 

(a)    Series A Corporation Redemption Date. Subject to applicable law, upon the business day established by the
Board of Directors at any time from time to time from and after the Series A Original Issue Date (such business day, the “Series A Corporation Redemption Date”), and without any action on the part of the Corporation or any holder of
outstanding shares of Series A Preferred Stock, one or more or all of the outstanding shares of Series A Preferred Stock (as determined by the Board of Directors) shall be redeemed by the Corporation on the Series A Corporation Redemption Date at
the Series A Redemption Price, which aggregate number of shares of Series A Preferred Stock to be redeemed shall be effected pro rata based on the number of outstanding shares of Series A Preferred Stock held by a holder bears to the number
of outstanding shares of Series A Preferred Stock held by all holders of Series A Preferred Stock. The Corporation shall provide (on a business day) written notice to the holders of outstanding shares of Series A Preferred Stock of the Series A
Corporation Redemption Date not less than ten (10) business days prior to the Series A Corporation Redemption Date setting forth (i) the Series A Corporation Redemption Date, (ii) the Series A Redemption Price and (iii) the
aggregate number of outstanding shares of Series A Preferred Stock to be redeemed by the Corporation on such Series A Corporation Redemption Date. 

(b)    Payment of the Series A Redemption Price. The Series A Redemption Price shall be paid in cash. Upon the
Series A Corporation Redemption Date, the Corporation shall, except to the extent prohibited by Delaware law governing distributions to stockholders, apply all of the assets of the Corporation to the payment of the Series A Redemption Price to the
holders of shares of Series A Preferred Stock entitled thereto, and to no other corporate purpose or purposes to the fullest extent permitted by applicable law. 

(c)    Delivery of the Series A Preference Price. The Corporation shall, as soon as practicable, and in no event
later than three (3) Trading Days after the Series A Corporation Redemption Date, deliver the Series A Redemption Price, in cash, to the holders of shares of Series A Preferred Stock entitled thereto by either (i) wire transfer, to an
account designated by the relevant holder by written notice delivered to the Corporation at the principal office of the Corporation or of any transfer agent for Series A Preferred Stock not less than two (2) business days prior to the Series A
Corporation Redemption Date, or (ii) delivery of a check, to the address of the relevant holder as shown on the books and records of the Corporation. 

(d)    Effect of Redemption. Redemption of one or more all of the outstanding shares of Series A Preferred Stock
pursuant to this Section 11 shall be deemed to have been made immediately prior to the close of business on the Series A Corporation Redemption Date. From and after the Series A Corporation Redemption Date, each share of Series A
Preferred Stock redeemed pursuant to this Section 11 shall no longer be deemed to be outstanding and all rights in respect of such share of Series A Preferred Stock shall cease, except for the right to receive the Series A Redemption
Price. 

  
 13 

 Section 12.    Redemption at the Option of a Holder. 

(a)    Qualifying Financing Period. Subject to applicable law, at any time from time to time during the five
(5) Trading Day period following a holder’s receipt of written notice pursuant to Section 12(b) or Section 12(c) (such period, the “Qualifying Financing Period”), each
holder of an outstanding share or shares of Series A Preferred Stock shall have the right to cause the Corporation to redeem, solely and exclusively out of the then aggregate Qualifying Financing Proceeds, any or all of the outstanding shares of
Series A Preferred Stock held by such holder at the Series A Redemption Price. 
 (b)    Notice of Qualifying
Financing Event. Not more than three (3) Trading Days after the occurrence of the Qualifying Financing Event, the Corporation shall deliver (on a business day) written notice to the holders of then outstanding shares of Series A Preferred
Stock and make a public announcement, in each case, of (i) the date of the occurrence of the Qualifying Financing Event and (ii) the then aggregate Qualifying Financing Proceeds. 

(c)    Quarterly Notice of Equity Financings. From and after the occurrence of the Qualifying Financing Event, not
more than three (3) Trading Days after each Series A Quarterly Dividend Payment Date following the date of the occurrence of the Qualifying Financing Event, the Corporation shall deliver (on a business day) written notice to the holders of the
then outstanding shares of Series A Preferred Stock and make a public announcement, in each case, of then then aggregate Qualifying Financing Proceeds. 

(d)    Mechanics of Redemption upon a Qualifying Financing. A holder of an outstanding share or shares of Series A
Preferred Stock desiring to cause the Corporation to redeem any or all of the outstanding shares of Series A Preferred Stock held by such holder pursuant to this Section 12 shall deliver (on a business day) written notice
thereof to the principal office of the Corporation or of any transfer agent for Series A Preferred Stock any time during the Qualifying Financing Period specifying the number of shares of outstanding Series A Preferred Stock held by such holder
proposed to be redeemed (if such notice is silent as to the number of outstanding shares of Series A Preferred Stock held by the holder and proposed to be redeemed pursuant to this Section 12, the notice shall be deemed to
apply to all outstanding shares of Series A Preferred Stock held by such holder), together with the certificate or certificates representing the outstanding shares of Series A Preferred Stock proposed to be redeemed under this
Section 12, duly indorsed for transfer to the Corporation (the business day on which such written notice and certificate or certificates are delivered to the Corporation pursuant to this
Section 12(d), the “Series A Optional Redemption Date”). 
 (e)    Payment
of the Series A Redemption Price. The Series A Redemption Price shall be paid in cash. Upon the Series A Optional Redemption Date, the Corporation shall, except to the extent prohibited by Delaware law governing distributions to stockholders,
apply all of the Qualifying Financing Proceeds to the payment of the Series A Redemption Price to the holders of outstanding shares of Series A Preferred Stock delivering a written notice and certificate or certificates pursuant to
Section 12(d) during any Qualifying Financing Period, and to no other 

  
 14 

 
corporate purpose or purposes to the fullest extent permitted by applicable law. If the Qualifying Financing Proceeds available for distribution under Delaware law governing distributions to
stockholders shall be insufficient to permit the payment of the Series A Redemption Price to all holders of outstanding shares of Series A Preferred Stock delivering a written notice and certificate or certificates pursuant to
Section 12(d) during any Qualifying Financing Period, then the entire Qualifying Financing Proceeds available for distribution under Delaware law governing distributions to stockholders shall be utilized to redeem ratably
among such holders of outstanding shares of Series A Preferred Stock. 
 (f)    Delivery of the Series A Redemption
Price. The Corporation shall, as soon as practicable, and in no event later than three (3) Trading Days after the Series A Optional Redemption Date, deliver the Series A Redemption Price, in cash, to the holder of shares of Series A
Preferred Stock entitled thereto by either (i) wire transfer, to an account designated by the relevant holder by in the written notice delivered by the holder pursuant to Section 12(d), or (ii) delivery of a
check, to the address of the relevant holder as shown on the books and records of the Corporation. 
 (g)    Effect
of Optional Redemption. Redemption of outstanding shares of Series A Preferred Stock pursuant to this Section 12 shall be deemed to have been made immediately prior to the close of business on the Series A Optional
Redemption Date. From and after the Series A Optional Redemption Date, each share of Series A Preferred Stock redeemed pursuant to this Section 12 shall no longer be deemed to be outstanding and all rights in respect of
such share of Series A Preferred Stock shall cease, except for the right to receive the Series A Redemption Price. 

Section 13.    Certificated or Uncertificated Shares of Series A Preferred Stock or Common Stock. 

(a)    Series A Preferred Stock. If at any time the Board of Directors shall have adopted a resolution or
resolutions providing that shares of Series A Preferred Stock shall be uncertificated shares, such resolution or resolutions shall not apply to a share of Series A Preferred Stock represented by a certificate until such certificate is surrendered to
the Corporation, and, from and after the effectiveness of such resolution or resolutions as to a share of Series A Preferred Stock, (i) provisions of this Certificate of Designation requiring the surrender of a certificate or certificates
representing or formerly representing such shares by a holder shall instead require the delivery of an instruction with a request to register transfer of such shares to the Corporation and (ii) provisions of this Certificate of Designation
requiring the delivery of a certificate or certificates representing such shares by the Corporation shall instead require the delivery of the notice contemplated by Section 151(f) of the DGCL. 

(b)    Common Stock. If at any time the Board of Directors shall have adopted a resolution or resolutions providing
that shares of Common Stock shall be uncertificated shares, such resolution or resolutions shall not apply to a share of Common Stock represented by a certificate until such certificate is surrendered to the Corporation, and, from and after the
effectiveness of such resolution or resolutions as to a share of Common Stock, provisions of this Certificate of Designation requiring the delivery of a certificate or certificates representing such shares by the Corporation shall instead require
the delivery of the notice contemplated by Section 151(f) of the DGCL. 

  
 15 

 Section 14.    Status of Converted, Redeemed or Repurchased
Shares. If any share of Series A Preferred Stock is converted, redeemed, repurchased or otherwise acquired by the Corporation in any manner whatsoever, the share of Series A Preferred Stock so acquired shall, to the fullest extent permitted by
applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series A Preferred Stock. Any share of Series A Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of
any action required by applicable law, become an authorized but unissued share of Preferred Stock undesignated as to series and may be reissued a part of a new series of Preferred Stock, subject to the conditions and restrictions set forth in the
Certificate of Incorporation or imposed by the DGCL. 
 Section 15.    Waiver. The voting powers, if any, of
the Series A Preferred Stock and the preferences and relative, participating, optional, special or other rights, if any, and the qualifications, limitations or restrictions, if any, of the Series A Preferred Stock may be waived as to all shares of
Series A Preferred Stock in any instance (without the necessity of calling, noticing or holding a meeting of stockholders) by the consent or agreement of the holders of at least ninety percent (90%) of the then outstanding shares of Series A
Preferred Stock, consenting or agreeing separately as a single class.” 
 [Signature Page Follows] 

  
 16 

 IN WITNESS WHEREOF, the undersigned has executed this Certificate of Designation of the
Series A Convertible Perpetual Preferred Stock of Comera Life Sciences Holdings, Inc. on this 19th day of May, 2022. 

 

			
	COMERA LIFE SCIENCES HOLDINGS, INC.
		
	By:	 	 /s/ Jeffrey Hackman

	Name:	 	Jeffrey Hackman
	Title:	 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]